Top

Drugs

Published in:

01-04-2002 | Adis New Indication Profile

Moxifloxacin

In Uncomplicated Skin and Skin Structure Infections

Authors: Richard B. R. Muijsers, Blair Jarvis

Published in: Drugs | Issue 6/2002

Abstract

▴ Moxifloxacin is a fluoroquinolone antibacterial agent which attains good penetration into peripheral tissues and inflammatory fluids. The drug shows good in vitro activity against staphylococci and streptococci. Moxifloxacin is therefore a suitable option for the treatment of uncomplicated skin and skin structure infections of bacterial origin.
▴ In clinical trials, moxifloxacin was as effective as cephalexin in the treatment of uncomplicated skin and skin structure infections in patients aged ≥18 years. Moxifloxacin 400mg once daily or cephalexin 500mg three times daily for 7 days both resulted in clinical resolution in 84% of patients during a double-blind, randomised trial in 401 patients (intent-to-treat). The main infectious agent in this study was Staphylococcus aureus. Similar results were obtained in two other randomised, double-blind trials published as abstracts.
▴ The bioavailability of moxifloxacin is substantially reduced by coadministration with antacids or iron preparations. Moxifloxacin, however, does not show pharmacokinetic interaction with theophylline or warfarin. Dosage adjustments are not required in patients with renal impairment or in patients with mild to moderate hepatic insufficiency.
▴ The most common adverse events reported during moxifloxacin treatment are gastrointestinal disturbances. The potential for photosensitivity reactions during moxifloxacin treatment is low.

Barman Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000 Jan; 59: 115–39CrossRef

Karchmer AW. Fluoroquinolone treatment of skin and skin structure infections. Drugs 1999; 58 Suppl. 2: 82–4PubMedCrossRef

Chan JC. Combating bacterial resistance in skin and skin-structure infection: importance of β-lactamase inhibition. Am J Ther 1999 Jan; 6: 13–8PubMedCrossRef

Bayer Corporation PD. Moxifloxacin (Avelox) prescribing information. Westhaven (CT): Bayer. 2001

National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria, 4th ed. Approved standard. Publication no. M11-A 4. 1998

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 8th informational supplement. Approved standard. Publication no. M100-S 8. 1998

National Committee for Clinical Laboratory Standards. Method for dilution antimicrobial susceptibility for bacteria that grow aerobically, 4th ed. Approved standard. Publication no. M7-A 4. 1997

National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria, 3rd ed. Approved standard. Publication no. M11-A 3. 1993

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, informational supplement. Approved standard. Publication no. M100-S10(M7). 2000

10.

Milatovic D, Schmitz F-J, Brisse S, et al. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000 Apr; 44: 1102–7PubMedCrossRef

11.

Jones ME, Visser MR, Klootwijk M, et al. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and non-quinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999 Feb; 43: 421–3PubMed

12.

Pong A, Thomson KS, Moland ES, et al. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 1999 Nov; 44: 621–7PubMedCrossRef

13.

Barry AL, Fuchs PC, Brown SD. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis 1999 Apr; 18: 305–9PubMedCrossRef

14.

Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against Gram-positive bacteria. Diagn Microbiol Infect Dis 1999 Oct; 35: 127–33PubMedCrossRef

15.

Boswell FJ, Andrews JM, Wise R, et al. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999 May; 43 Suppl. B: 43–9PubMedCrossRef

16.

Pfeil E, Wiedemann B. Pronounced postantibiotic effect of quinupristin-dalfopristin in static cultures of Staphylococcus aureus: an effect not seen with other antibiotics. Antimicrob Agents Chemother 2000 Apr; 44: 1059–61PubMedCrossRef

17.

Dalhoff A. Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother 1999 May; 43 Suppl. B: 51–9PubMedCrossRef

18.

Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001 Mar 15; 32 Suppl. 1: S33–8PubMedCrossRef

19.

Schedletzky H, Wiedemann B, Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1999 May; 43 Suppl. B: 31–7PubMedCrossRef

20.

Schmitz F-J, Hofmann B, Hansen B, et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998 Apr; 41(4): 481–4PubMedCrossRef

21.

Schmitz F-J, Fluit AC, Luckefahr M, et al. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998 Dec; 42(6): 807–10PubMedCrossRef

22.

Müller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999 Oct; 43(10): 2345–9PubMed

23.

Wise R, Andrews JM, Marshall G, et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999 Jun; 43(6): 1508–10PubMed

24.

Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999 May; 43 Suppl. B: 83–90PubMedCrossRef

25.

Lettieri J, Vargas R, Agarwal V, et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 19–25PubMedCrossRef

26.

Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 33–8PubMedCrossRef

27.

Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001 Mar 15; 32 Suppl. 1: S47–50PubMedCrossRef

28.

Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002 Mar; 53(3): 232–7PubMedCrossRef

29.

Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H₂ antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 39–48PubMedCrossRef

30.

Stass H, Schuhly U, Möller J-G, et al. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 49–55PubMedCrossRef

31.

Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin Pharmacokinet 2001; 40 Suppl. 1: 57–62PubMedCrossRef

32.

Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 27–32PubMedCrossRef

33.

Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin Pharmacokinet 2001; 40 Suppl. 1: 63–70PubMedCrossRef

34.

Hollister AS, Agarwal V, Dain B, et al. Absence of drug interaction between oral moxifloxacin and intramuscular morphine sulfate in healthy volunteers. Clin Drug Invest 2001; 21(1): 79–85CrossRef

35.

Stass H, Sachse R. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001; 40 Suppl. 1: 71–6PubMedCrossRef

36.

Leal del Rosal P, Fabian G, Vick-Fragoso R, et al. Efficacy and safety of moxifloxacin (MXF) vs cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections (USSSI) [abstract]. J. Antimicrob Chemother. 21st International Congress of Chemotherapy; 1999 Sep 26–29; San Francisco (CA). 44 Suppl. A (plus poster)

37.

Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000 Oct; 54(8): 497–503PubMed

38.

Leal del Rosal P, Fabian G, Vick-Fragoso R, et al. Efficacy and safety of moxifloxacin (MXF) vs cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSI) [abstract]. 39th ICAAC; 1999 Sep 26;: 716 (plus poster)

39.

Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Today’s Ther Trends 2000; 18(3): 205–23

Title: Moxifloxacin
In Uncomplicated Skin and Skin Structure Infections
Authors: Richard B. R. Muijsers
Blair Jarvis
Publication date: 01-04-2002
Publisher: Springer International Publishing
Published in: Drugs / Issue 6/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200262060-00008

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Moxifloxacin

In Uncomplicated Skin and Skin Structure Infections

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2002

Pharmacological Approaches for the Treatment of Obesity

Novel Pharmacotherapeutic Approaches to Prevention and Treatment of GVHD

NSAIDs and Gastrointestinal Cancer Prevention

Treatment of Sexually Transmitted Infections with Single-Dose Therapy

Moxifloxacin

Newer Immunosuppressive Drugs